Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation

References

• Strazzullo P, D’Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke. 2010;41(5):e418–e426. doi:10.1161/STROKEAHA.109.57696720299666
   PubMed Web of Science ®Google Scholar
• Sonnenberg G, Krakower G, Kissebah A. A novel pathway to the manifestations of metabolic syndrome. Obes Res. 2004;12:180e186. doi:10.1038/oby.2004.2414981209
   PubMedGoogle Scholar
• Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278:F817–F822. doi:10.1152/ajprenal.2000.278.5.F81710807594
   PubMed Web of Science ®Google Scholar
• Wallace JL, Reaves AB, Tolley EA, et al. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis. 2013;36:96–101. doi:10.1007/s11239-012-0811-x23015280
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa090556119717844
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa100963821830957
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa110703921870978
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi:10.1056/NEJMoa131090724251359
   PubMed Web of Science ®Google Scholar
• Russo V, Bianchi V, Cavallaro C, et al. Efficacy and safety of dabigatran in a “real-life” population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Eur Rev Med Pharmacol Sci. 2015;19(20):3961–3967.26531286
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Proietti R, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017;8(2):67–75. doi:10.1177/204209861667399028255434
   PubMed Web of Science ®Google Scholar
• Russo V, Attena E, Mazzone C, et al. Real-life performance of edoxaban in elderly patients with atrial fibrillation: a multicenter propensity Score-Matched Cohort Study. Clin Ther. 2019;41(8):1598–1604. doi:10.1016/j.clinthera.2019.04.04131151813
   PubMed Web of Science ®Google Scholar
• Russo V, Carbone A, Rago A, Golino P, Nigro G. Direct oral anticoagulants in octogenarians with atrial fibrillation: it’s never too late. J Cardiovasc Pharmacol. 2019;73(4):207–214. doi:10.1097/FJC.000000000000066130855404
   PubMed Web of Science ®Google Scholar
• Verdecchia P, D’Onofrio A, Russo V, et al. Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. J Cardiovasc Med (Hagerstown). 2019;20(2):66–73. doi:10.2459/JCM.000000000000074430540644
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Proietti R, et al. Safety and efficacy of triple antithrombotic therapy with dabigatran versus vitamin k antagonist in atrial fibrillation patients: a pilot study. Biomed Res Int. 2019;2019:5473240. doi:10.1155/2019/547324030895193
   PubMed Web of Science ®Google Scholar
• Martin K, Beyer‐Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:1308–1313. doi:10.1111/jth.1332327299806
   PubMed Web of Science ®Google Scholar
• Self TH, Wallace JL, Sakaan S, Sands CW. Effect of body weight on dose of vitamin K antagonists. South Med J. 2015;108(10):637–643. doi:10.14423/SMJ.000000000000035626437201
   PubMed Web of Science ®Google Scholar
• Kido K, Ngorsuraches S. Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. Ann Pharmacother. 2018;22:1060028018796604.
   Google Scholar
• Sandhu RK, Ezekowitz J, Andersson U, et al. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. Eur Heart J. 2016;37(38):2869–2878. doi:10.1093/eurheartj/ehw12427071819
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation. 2019;139(20):2292–2300. doi:10.1161/CIRCULATIONAHA.118.03795530773022
   PubMed Web of Science ®Google Scholar
• Piran S, Traquair H, Chan N, Bhagirath V, Schulman S. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. Res Pract Thromb Haemost. 2018;2(4):684–688. doi:10.1002/rth2.1214630349887
   PubMed Web of Science ®Google Scholar
• Boriani G, Ruff CT, Kuder JF, et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019;40(19):1541–1550. doi:10.1093/eurheartj/ehy86130624719
   PubMed Web of Science ®Google Scholar
• Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908–916. doi:10.1111/bcp.2013.76.issue-623488672
   PubMed Web of Science ®Google Scholar
• Russo V, Bottino R, Rago A, et al. Atrial fibrillation and malignancy: the clinical performance of non-vitamin K oral anticoagulants – a systematic review. Semin Thromb Hemost. 2019;45(2):205–214. doi:10.1055/s-0038-166138630119139
   PubMed Web of Science ®Google Scholar
• Russo V, Attena E, Mazzone C, et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost. 2018;44(4):364–369. doi:10.1055/s-0037-161526129304513
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Papa AA, et al. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with malignancy: clinical practice experience in a single institution and literature review. Semin Thromb Hemost. 2018;44(4):370–376. doi:10.1055/s-0037-160743629220855
   PubMed Web of Science ®Google Scholar
• Rago A, Papa AA, Cassese A, et al. Clinical performance of apixaban vs. Vitamin K antagonists in patients with atrial fibrillation undergoing direct electrical current cardioversion: a prospective propensity Score-Matched Cohort Study. Am J Cardiovasc Drugs. 2019;19(4):421–427. doi:10.1007/s40256-019-00341-930838557
   PubMed Web of Science ®Google Scholar
• Russo V, Rago A, Papa AA, D’Onofrio A, Golino P, Nigro G. Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. J Thromb Thrombolysis. 2018;45(2):206–212. doi:10.1007/s11239-017-1599-529260427
   PubMed Web of Science ®Google Scholar